Literature DB >> 31181374

Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.

Etienne Puymirat1, Guillaume Cayla2, Yves Cottin3, Meyer Elbaz4, Patrick Henry5, Edouard Gerbaud6, Gilles Lemesle7, Batric Popovic8, Jean-Noel Labèque9, François Roubille10, Stéphane Andrieu11, Bruno Farah12, François Schiele13, Jean Ferrières14, Tabassome Simon15, Nicolas Danchin16.   

Abstract

The increased use of reperfusion therapy in ST-segment-elevation myocardial infarction (STEMI) patients in the past decades is generally considered the main determinant of improved outcomes. The aim was to assess 20-year trends in profile, management, and one-year outcomes in STEMI patients in relation with use or non-use of reperfusion therapy (primary percutaneous coronary intervention (pPCI) or fibrinolysis).
METHODS: We used data from 5 one-month French nationwide registries, conducted 5 years apart from 2005 to 2015, including 8579 STEMI patients (67% with and 33% without reperfusion therapy) admitted to cardiac intensive care units in France.
RESULTS: Use of reperfusion therapy increased from 49% in 1995 to 82% in 2015, with a shift from fibrinolysis (37.5% to 6%) to pPCI (12% to 76%). Early use of evidence-based medications gradually increased over the period in both patients with and without reperfusion therapy, although it remained lower at all times in those without reperfusion therapy. One-year mortality decreased in patients with reperfusion therapy (from 11.9% in 1995 to 5.9% in 2010 and 2015, hazard ratio [HR] adjusted on baseline profile 0.40; 95% CI: 0.29-0.54, P < .001) and in those without reperfusion therapy (from 25.0% to 18.2% in 2010 and 8.1% in 2015, HR: 0.33; 95% CI: 0.24-0.47, P < .001).
CONCLUSIONS: In STEMI patients, one-year mortality continues to decline, both related to increased use of reperfusion therapy and progress in overall patient management. In patients with reperfusion therapy, mortality has remained stable since 2010, while it has continued to decline in patients without reperfusion therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31181374     DOI: 10.1016/j.ahj.2019.05.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.

Authors:  Mustafa Kemal Erol; Meral Kayıkçıoğlu; Mustafa Kılıçkap; Can Baba Arın; Ibrahim Halil Kurt; Ibrahim Aktaş; Yılmaz Güneş; Eyüp Özkan; Taner Şen; Orhan Ince; Ender Örnek; Ramazan Asoğlu; Nesim Aladağ; Utku Zeybey; Ümit Yaşar Sinan; Muhammet Dural; Haşim Tüner; Arda Doğan; Mustafa Yenerçağ; Mehmet Akboğa; Onur Sinan Deveci; Mustafa Umut Somuncu
Journal:  Anatol J Cardiol       Date:  2020-07       Impact factor: 1.596

2.  Aminooxyacetic acid attenuates post-infarct cardiac dysfunction by balancing macrophage polarization through modulating macrophage metabolism in mice.

Authors:  Pei Zhao; Wenjing Zhou; Yanxia Zhang; Jingjing Li; Ye Zhao; Lihua Pan; Zhenya Shen; Weiqian Chen; Jie Hui
Journal:  J Cell Mol Med       Date:  2020-01-13       Impact factor: 5.310

3.  Characteristics and outcomes of young patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: retrospective analysis in a multiethnic Asian population.

Authors:  Benjamin Wl Tung; Zhe Yan Ng; William Kristanto; Kalyar Win Saw; Siew-Pang Chan; Winnie Sia; Koo Hui Chan; Mark Chan; William Kong; Ronald Lee; Joshua P Loh; Adrian F Low; Kian Keong Poh; Edgar Tay; Huay Cheem Tan; Tiong-Cheng Yeo; Poay Huan Loh
Journal:  Open Heart       Date:  2021-01

4.  Cardiovascular diseases mortality and alcohol control policy in Lithuania: exploring a possible link.

Authors:  Ricardas Radisauskas; Kawon Victoria Kim; Shannon Lange; Vaida Liutkute-Gumarov; Olga Mesceriakova-Veliuliene; Janina Petkeviciene; Mindaugas Stelemekas; Tadas Telksnys; Alexander Tran; Jürgen Rehm
Journal:  BMC Public Health       Date:  2021-11-17       Impact factor: 3.295

5.  Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy.

Authors:  Rohin Francis; Jun Chong; Heerajnarain Bulluck; Derek J Hausenloy; Manish Ramlall; Chiara Bucciarelli-Ducci; Tim Clayton; Matthew Dodd; Thomas Engstrøm; Richard Evans; Vanessa M Ferreira; Marianna Fontana; John P Greenwood; Rajesh K Kharbanda; Won Yong Kim; Tushar Kotecha; Jacob T Lønborg; Anthony Mathur; Ulla Kristine Møller; James Moon; Alexander Perkins; Roby D Rakhit; Derek M Yellon; Hans Erik Bøtker
Journal:  Basic Res Cardiol       Date:  2021-10-14       Impact factor: 17.165

6.  Validated Impacts of N6-Methyladenosine Methylated mRNAs on Apoptosis and Angiogenesis in Myocardial Infarction Based on MeRIP-Seq Analysis.

Authors:  Yingjie Zhang; Wenjie Hua; Yini Dang; Yihui Cheng; Jiayue Wang; Xiu Zhang; Meiling Teng; Shenrui Wang; Min Zhang; Zihao Kong; Xiao Lu; Yu Zheng
Journal:  Front Mol Biosci       Date:  2022-01-28

7.  The LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study.

Authors:  Ruochen Zhang; Yan Fan; Yanbo Xue; Yunfei Feng; Caijuan Dong; Yamei Wang; Puqing Kou; Guoli Li; Aiqun Ma; Tingzhong Wang
Journal:  Braz J Med Biol Res       Date:  2022-02-04       Impact factor: 2.590

8.  Early survival after acute myocardial infarction with ST-segment elevation: What could be improved? Insights from France PCI French registry.

Authors:  Benjamin Duband; Pascal Motreff; Pierre Marcollet; Alexandre Gamet; Marie-Pascale Decomis; Olivier Bar; Christophe Saint Etienne; Radwan Hakim; Alexandre Canville; Louis Viallard; Farzin BeyguI; Pierre Francois Lesault; Philippe Bonnet; Eric Durand; Emmanuel Boiffard; Jean-Philippe Collet; Hakim Benamer; Philippe Commeau; Guillaume Cayla; Bruno Pereira; Rene Koning; Gregoire Rangé
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.